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Abstract Thyroid hormone (TH/T3) exerts many of its e¡ects
on energy metabolism by a¡ecting gene transcription. However,
although this is an important target for T3, only a limited
number of T3-responsive genes have been identi¢ed and studied.
Among these, the genes for uncoupling proteins (UCPs) have
attracted the interest of scientists. Although the role of UCP1
seems quite well established, uncertainty surrounds the physio-
logical function of the recently discovered UCP1 analogs,
UCP2 and UCP3. The literature suggests that T3 a¡ects both
the expression and the activity of each of these UCPs but fur-
ther studies are needed to establish whether the mechanisms
activated by the hormone are the same. Recently, because of
their larger range of expression, much attention has been de-
voted to UCP2 and UCP3. Most detailed studies on the involve-
ment of these proteins as mediators of the e¡ects of T3 on
metabolism have focused on UCP3 because of its expression
in skeletal muscle. T3 seems to be unique in having the ability
to stimulate the expression and activity of UCP3 and this may
be related to the capacity of T3 to activate the integrated bio-
chemical processes linked to UCP activity, such as those related
to fatty acids, coenzyme Q and free radicals.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
For the maintenance of a stable body weight, energy intake
needs to match energy expenditure. A multitude of factors
contribute to this stability, including genetic, physiological
and behavioral factors. From a thermodynamic point of
view, and considering the animal as a thermodynamic system,
we can state that when the ‘energy potential’ of a system does
not change all the energy expended in a transformation of the
system appears, ultimately, as heat. This is certainly true in
adult animals. In this state, the animal consumes oxygen to
perform ‘internal and external work’ and the energy it ex-
pends may be measured either as oxygen consumption (indi-
rect calorimetry) or as the heat produced (direct calorimetry),
hence the terms ‘calorigenesis’ and ‘thermogenesis’. Direct
calorimetry, which may represent the best way to measure
energy expenditure, was often used in the past. However, in
the knowledge that there is a good correspondence among
energy expenditure, heat production and oxygen consump-
tion, the evaluation of energy expenditure is now most often
achieved by measuring oxygen consumption.
Energy expenditure basically consists of three components:
(a) obligatory energy expenditure (or basal thermogenesis),
(b) facultative energy expenditure (or adaptative thermogene-
sis) and (c) voluntary energy expenditure.
Basal thermogenesis is represented by the heat produced (or
oxygen consumed) as a by-product of the sum of all the ana-
bolic and catabolic biochemical processes involved in the
maintenance of the functions essential for life (respiration,
circulation etc.). In poikilotherms (or ectotherms), this use
of energy is minimal, but in homeotherms (or endotherms)
basal thermogenesis is important to maintain a steady level
of body temperature. About 20 years ago, Danforth and Bur-
ger [1] further divided this component into essential heat and
obligatory heat.
Essential heat represents the energy lost (as heat) as a by-
product of all the ‘life-essential’ metabolic processes. Under
most circumstances in homeotherms, this heat is insu⁄cient to
maintain the body temperature and is supplemented by addi-
tional heat production termed obligatory heat.
It is by now an historical notion that thyroid hormones
(THs) are unique in their ability to stimulate basal thermo-
genesis. In fact, among the most pronounced physiological
e¡ects attributed to THs is their in£uence over metabolism
in adult endotherms. However, although this e¡ect was de-
duced more than 100 years ago [2] and the demonstration that
THs increase energy expenditure by lowering metabolic e⁄-
ciency dates from the 1950s, it is surprising how little is
known even now about the cellular^molecular mechanisms
underlying these e¡ects.
Over the years, several biochemical processes have been put
forward to explain the mechanism by which THs stimulate
thermogenesis [3]. Now, the control of speci¢c genes at the
transcriptional level is thought to be the major molecular
mechanism. However, both the number and the identity of
the TH-controlled genes remain unknown, as do their relative
contributions.
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Be that as it may, our knowledge of the mechanisms under-
lying thermogenesis and its control implies the involvement,
directly or indirectly, of the mitochondrial energy-transduc-
tion apparatus [4]. About 50 years ago, it was suggested
that THs increase metabolic rate by uncoupling electron
transport from ATP synthesis [5]. This hypothesis was subse-
quently discarded because it was thought not to be physiolog-
ically relevant: the e¡ects seen in vitro were not observed in
vivo. More recently, however, the uncoupling hypothesis has
gained new support because:
b in mitochondria, oxygen consumption is not perfectly
coupled to ATP synthesis, part of the proton electrochem-
ical gradient being dissipated as heat. Two main mecha-
nisms may explain this imperfect coupling: passive re-entry
of protons inside the matrix (proton-leak) and a failure of
the proton pumps consisting in a reduced extrusion of pro-
tons in spite of the same electron transport rate (redox-slip).
It now seems quite well established that proton-leakage is a
general property of the inner mitochondrial membrane;
b it has been discovered that uncoupling proteins (UCPs) are
present in almost all tissues and, due to their putative in-
volvement in the mechanisms underlying cellular thermo-
genesis, they are obvious candidates as mediators of thyroid
thermogenesis.
2. UCPs
The proton-leak across the inner mitochondrial membrane
accounts for a signi¢cant part of an animal’s resting metabolic
rate and it represents a potential mechanism for energy dis-
sipation or heat production. At the mitochondrial level, two
types of proton-leak have been described: basal and inducible.
The former is present in mitochondria in every tissue and,
while the mechanism regulating it is not clear, it may be re-
lated to the lipidic environment of the membrane [6]. The
inducible proton-leak, on the other hand, occurs through spe-
ci¢c UCPs and is tightly regulated [7].
UCPs are homologous proteins constituting a subfamily of
mitochondrial anion carriers [8] that are evolutionarily related
and possibly derived from an ancestral protein that acted as a
proton/anion carrier. UCP1, cloned in 1985 and called UCP
until 1997, is located on human chromosome 4 and is exclu-
sively expressed in brown adipose tissue (BAT) (for review,
see [9]). Located in the inner mitochondrial membrane of
BAT cells, UCP1, by uncoupling BAT mitochondria, leads
to a physiologically important, hormonally regulated, heat
production in response to cold or an inadequate diet, al-
though some doubts have emerged recently concerning the
latter mechanism [10].
Since 1997, several genes have been discovered that encode
proteins closely related to the UCP1. In mammals, four such
genes have been described: UCP2, UCP3, UCP4 and BMCP1
(brain mitochondrial carrier protein 1, also termed UCP5).
This article will focus in particular on UCP1, UCP2 and
UCP3.
UCP2 and UCP3 are adjacent genes located on human
chromosome 11 at loci genetically linked to obesity and dia-
betes [9]. In contrast to UCP1, both UCP2 and UCP3 are
expressed to a substantial degree in adult humans. UCP2
mRNA is present in a large number of tissues and is at
high levels in white adipose tissue (WAT), spleen and pancre-
atic L-cells. Despite the ubiquitous presence of UCP2 mRNA,
UCP2 protein has been detected in only few tissues [11].
UCP3 mRNA is strongly expressed in skeletal muscle and
to a lesser extent in heart, BAT and WAT, while UCP4
mRNA is present in brain and the mRNAs for BMCP1/
UCP5 are present in brain and liver (for review, see [9,12]).
The homology of both UCP2 and UCP3 (55% and 57%, re-
spectively) with UCP1 has led to the assumption that they
also have a speci¢c proton/anion carrier function. Indeed,
the idea that UCP analogs might be expected to function as
uncouplers was perhaps responsible for orienting the early
investigations on the novel UCPs. However, the functions of
UCP2 and UCP3 remain uncertain. They have been demon-
strated to uncouple mitochondrial oxidative phosphorylation
in a number of experimental models such as proteoliposomes
[13,14], yeast heterologous expression systems [15,16] and
transgenic mice [17,18], and it is now quite clear that heterol-
ogous or transgenic expression of these proteins leads to an
increase in the proton conductance of the inner membrane.
However, it is less obvious whether these uncouplings are due
to the activity of the UCP1 homologs or instead represent a
more general perturbation of mitochondrial function [19].
An increase in the levels of the mRNAs for UCP2 and
UCP3 has been shown not only in situations in which energy
expenditure is signi¢cantly increased (fever [20], hyperthyroid-
ism [21^23], high levels of leptin [24], cold exposure [25]) but
also in one in which it would be expected to be depressed
(starvation [26]). As yet, an increased expression of UCP ana-
logs has not always been shown to be associated with in-
creased mitochondrial uncoupling [27,28]. These results
prompted the hypothesis that uncoupling is not the primary
function of the newly discovered UCPs but rather a conse-
quence of their real function. In particular, it has been hy-
pothesized that UCPs may be involved in the handling of
lipids, although whether such a physiological role of UCP2/
UCP3 might be related to the control of lipid oxidation or to
the prevention of lipotoxicity is unclear [29]. The observations
that in skeletal muscle various physiological conditions asso-
ciated with increased fat metabolism are correlated with a
raised UCP3 mRNA expression and that UCP3 mRNA levels
are ‘lipid-sensitive’ constitutes evidence that the association
between UCP3 expression and fat metabolism is strong. Ago-
nists of peroxisome proliferator-activated receptors (PPARs)
(K and Q) a¡ect the expressions of UCP3, indicating that these
transcription factors, which are regulated by lipid metabolites,
are involved in this association. Response elements for both
TRs and PPARs have been shown to reside within the UCP3
promoter, although to our knowledge they are lacking in the
UCP2 gene. Medvedev et al. have shown that the regulation
of UCP2 expression is mediated indirectly by PPARQ through
two E-box motifs in the UCP2 promoter, without PPAR
binding being involved [30].
An involvement of fatty acids is inherent in some hypoth-
eses put forward to explain the mechanism by which UCP1
elicits an uncoupling e¡ect [31]. According to the proton-bu¡-
ering model (see point A in Fig. 1), fatty acid-carboxyl groups
act as Hþ bu¡ers in conjunction with resident Hþ-bu¡ering
amino acids in the translocation channel of UCP1, while in
the ‘fatty acid acting as a cycling protonophore’ model, UCP1
is an anion carrier able to transport fatty acid anions outward
[32]. In the intermembrane space, anions are protonated and
return by a £ip-£op mechanism into the matrix, where Hþ
ions are released (see point C in Fig. 1). These hypotheses
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are still under investigation and actually there are arguments
for and against both models [33]. It has also been suggested
that the activators of UCP1 are most likely not free fatty acids
(FFAs) themselves but instead a fatty acid metabolite [34].
As an alternative, in the model proposed by Himms-Hagen
and Harper [35], UCP3 is postulated to function as a trans-
porter protein. However, the energy cost of operating of this
cycle would result from the ATP utilization needed for cyclic
fatty acid activation rather than from uncoupling via proton
entry [35]. According to their model, UCP3 would function in
concert with mitochondrial thioesterase I (a matrix enzyme
that cleaves activated long-chain fatty acids to their corre-
sponding FFAs and CoA-SH) to remove FFA anions from
the matrix by transporting them across the inner membrane,
thus allowing their return to the pool of fatty acid within the
cytosol (see point D in Fig. 1). However, in this model UCP3
cannot maintain a steady transmembrane gradient of free
non-oxidized fatty acids. Indeed, it is quite conceivable that
it would be impossible to avoid protonation of fatty acid
anions on the outer surface of the inner membrane and a
subsequent downhill £ip-£op of protonated fatty acids from
the outer to the inner membrane lea£et. In addition, the hy-
pothesis of Himms-Hagen and Harper does not explain the
antioxidant e¡ects exhibited by UCP2 and UCP3.
In fact, it has been proposed that the UCP1 homologs
could be proteins that participate in the modulation of mito-
chondrial reactive oxygen species (ROS) production and
therefore in the control of the redox state and oxidative stress
of the cell (for review, see [29]). In fact, according to the ear-
lier hypothesis of Skulachev [36], even if the uncoupling ac-
tivity of a given UCP1 homolog is weak and di⁄cult to detect
under physiological conditions, it may have an important role
in the mediation of ‘mild uncoupling’ and hence in the control
of ROS production within the cell (see point B in Fig. 1).
Evidence supporting such a role for UCP3 can be derived
from studies revealing that skeletal muscle mitochondria
from UCP3-knockout mice show a reduced proton-leak and
increased ROS production [37]. A role for UCP2 in limiting
ROS production and in the prevention of excess oxidative
damage has been proposed by Ne'gre-Salvayre et al. [38]
who showed an increased mitochondrial membrane potential
and H2O2 generation in mitochondria not expressing UCP2.
Arsenijevic et al. [39] demonstrated that macrophages from
mice with disruption within the UCP2 gene generated more
ROS and that these mice had greater resistance to parasitic
infection than wild-type mice.
As stated before, an increase in the UCP analogs level has
not always been found to be associated with an increased
proton-leak. In recent years, however, it has become evident
that a lack of mitochondrial uncoupling despite an upregula-
tion of UCPs protein levels does not necessarily mean that
they are devoid of the capacity to uncouple. Instead, the
above situation might be the result of lowered concentrations
of one or more putative cofactors. In fact, it seems clear that
UCP-mediated uncoupling activity depends not only on FFA
but also on factors such as coenzyme Q (CoQ) and super-
oxide.
Echtay et al. [14], who observed that CoQ is an obligatory
cofactor for the uncoupling activities of UCPs in liposomes,
suggested a role for CoQ consisting in a co-operation with
fatty acids based on the physical contact between these two
components at the membrane^UCP1 interface [14]. Further
Fig. 1. The scheme illustrates the various hypotheses on UCP analog functions. (A) UCPs as uncouplers; (B) UCPs as ROS-activated mild un-
couplers; (C) UCPs as fatty acid anions (FA3) carrier implied in the FA cycle across the inner membrane; (D) UCPs (in particular UCP3) as
FA3 exporters. For further details see the text.
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studies showed that CoQ increased proton conductance in rat
kidney (where UCP2 mRNA was present) but not in liver
mitochondria (where UCPs are absent), that this increase re-
quired fatty acids, that it was prevented by guanosine diphos-
phate (GDP) and that it was abolished by superoxide dismu-
tase (SOD), indicating that CoQ might mediate uncoupling
through the production of superoxide [40]. These results have
been questioned by Couplan et al. [41]. Ecthay et al. [42]
showed that superoxide increases mitochondrial proton con-
ductance through e¡ects on UCP1, UCP2 and UCP3, and
that such superoxide-induced uncoupling requires fatty acids
and is inhibited by purine nucleotides (see point B in Fig. 1).
They suggested that an interaction of superoxide with UCPs
could be a mechanism for decreasing the concentration of
ROS inside mitochondria [42] (for a schematic representation
of the hypothesized functions of UCP, see Fig. 1). However, a
still unknown function of UCP analogs, but possibly related
to functions A, B, C and D in Fig. 1, may exist.
2.1. THs and UCPs
2.1.1. THs. Many of the physiological e¡ects of T3 within
cells are exerted at the level of transcription via interactions
with speci¢c TH receptors (TRK and TRL) belonging to the
superfamily of nuclear hormone receptors (for reviews, see
[43]).
Although transcription is considered an important target
for THs, only a limited number of genes directly regulated
by TH has been identi¢ed (for review, see [44]). Recently,
the introduction of quantitative £uorescent cDNA microar-
rays has allowed the identi¢cation of several novel T3-respon-
sive genes both in rat [45] and human [46] which are both
positively and negatively regulated. Among the T3-responsive
genes detected so far, there are several nuclear-encoded respi-
ratory genes, although it is as yet unclear whether or not these
genes are directly regulated via an interaction of the T3^TR
complexes with TREs in their promoter regions (for review,
see [47]). Indirect induction has been suggested to occur via
activation of intermediate cofactors as the nuclear respiratory
factors-1 and -2 (NRF-1 and NRF-2) [48] or the thermogenic
PPARQ co-activator 1 (PGC1) [49] or the recently character-
ized PGC1-related co-activator [50].
T3 also regulates the transcription of mitochondrial DNA
[51]. A two- to eight-fold increase in the steady-state concen-
tration of all mitochondrial RNAs after 1^3 days of T3 treat-
ment has been reported [52]. This action might be exerted
either directly through the binding of T3 to speci¢c mitochon-
drial T3 receptors or indirectly through an induction of the
expression of mitochondrial transcription factor A (actually, a
nuclear-encoded gene [53]). Among the genes responsive to
T3, those for UCPs have recently attracted the attention of
scientists investigating the e¡ects of T3 on energy metabolism
(see below).
2.1.2. THs and UCP1. TH, in synergism with the sympa-
thetic nervous system, is involved in BAT cold-induced ther-
mogenesis (for review, see [54]). Hypothyroid rats do not sur-
vive cold well and fail to increase BAT recruitment (measured
as UCP1 concentration and activation) in response to nor-
adrenaline (NA). Although administration of physiological
doses of T4 restores cold survival and BAT recruitment, the
observation that higher doses of T4 are associated with a
blunted BAT response to cold led to the idea that TH played
only a permissive role in BAT-mediated thermogenesis. How-
ever, it later emerged that this permissive role was apparent
rather than real.
In fact, it has been shown that the BAT content of T3 is
strongly in£uenced by type II iodothyronine 5P-deiodinase
(D2), which converts T4 into T3, and that D2 is activated
by the sympathetic nervous system and inhibited powerfully
by its substrate, T4. UCP1 levels vary with the T3 concentra-
tion in BAT, and D2 provides the T3 necessary for a maximal
thermogenic response to adrenergic stimulation. The ¢nding
that T3 and the SNS interact in BAT-mediated thermogenesis
is explained by mechanisms operating at the level of the UCP1
gene, which is under the tight control of NA and T3 (for
review, see [54]).
The molecular basis of such synergism relies on the pres-
ence of two functional TREs and a cAMP-response element in
the UCP1 gene promoter and on the proteins involved in
cAMP generation [55].
2.1.3. THs, UCP2 and UCP3. Since the discovery of
UCP2 and UCP3 in most tissues in mammals, including hu-
mans, and the proposal that they play putative roles as un-
couplers, many studies have been performed to try to disclose
an involvement of these proteins in the e¡ect exerted by TH
on energy expenditure. Administration of T3 to rodents leads
to increases in the expressions of UCP2 and UCP3 in heart
and skeletal muscle [21^23]. In association with the hypothy-
roidism^hyperthyroidism transition, increases occur in UCP3
mRNA expression in skeletal muscle and in mitochondrial
uncoupling activity [23]. The latter result has been con¢rmed
in vivo by a non-invasive method (nuclear magnetic resonance
spectroscopy) both in rats and humans [56,57]. In rats, T3
administration led to an increased mitochondrial tricarboxylic
acid (TCA) £ux with a concomitant unchanged rate of ATP
synthesis and, consequently, a lowered ATP/TCA £ux ratio.
In hypothyroid rats given a single injection of T3, a strict
correlation in terms of time course has been shown among
the induced increase in UCP3 protein levels in gastrocnemius
muscle, the decrease in mitochondrial respiratory e⁄ciency
and the increase in the RMR of the whole animal [58]. In
that study, the maximal increase in mitochondrial UCP3 den-
sity was reached at 65 h after the T3 injection, and the in-
crease in RMR showed the same time course. At the same
time point, mitochondria isolated from gastrocnemius muscle
showed a signi¢cantly higher non-phosphorylating respiration
rate, whereas the membrane potential showed a decrease,
clearly indicating the occurrence of uncoupling [58]. These
data provide in vivo evidence that UCP3 has the potential
to act as a molecular determinant in the in£uence of T3
over RMR. In addition, Barbe et al. [59] have shown that
T3 upregulates UCP2 and UCP3 mRNA expressions in hu-
man skeletal muscle and adipose tissue both in vitro and in
vivo. In the above study [59], the increase in plasma free T3
levels that occurred following the T3 injection was associated
with an increase in RMR and a decreased respiratory quo-
tient, thus further pointing towards a role for UCP3 in the
e¡ect of T3 on resting metabolism. All these data are in favor
of a T3-promoted increase in thermogenesis also via a mito-
chondrial uncoupling in skeletal muscle.
In contrast to these observations, it has been reported that
UCP3 null mice given a 4 day course of T3 (at 100 Wg/100 g
body weight/day) show the same increase in RMR as wild-
type controls [18], a ¢nding that does not seem to support the
involvement of UCP3 in the T3-induced increase in metabolic
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rate. The discrepancy between this conclusion and the idea
that UCP3 plays a role in TH-induced thermogenesis may
be apparent rather than real. Among the possible reasons
for the discrepancy being apparent are: (1) the very high doses
of T3 used in UCP3-knockout studies (which could have over-
stimulated other thermogenetic mechanisms) and (2) in the
same study, the possible conversion of T3 to other thermo-
genic iodothyronines, such as 3,5-diiodothyronine [60].
2.1.4. Does T3 activate the integrated biochemical pathway
linked to UCP3 activity?. From an analysis of the literature
it seems evident that in various situations in which there is an
upregulation of UCP2 and UCP3, the THs are unique in their
capacity to regulate the expressions of UCPs while at the same
time to inducing mitochondrial uncoupling. This could be a
consequence of their capacity to synergistically stimulate, or
interact with, the complex network of biochemical pathways
underlying the activation of UCPs (such as those related to
FFA, CoQ and ROS) (see Fig. 2). Actually, TH is well known
to induce lipolysis and thus at least part of the e¡ect of T3 on
the expression of the UCPs could be due to newly released
FFA.
The increase in FFA associated with hyperthyroidism can
also a¡ect the functionality of UCP3 within the mitochondria.
The clear-cut changes in proton-leak kinetics in rat skeletal
muscle mitochondria that accompany the hypothyroidism^hy-
perthyroidism transition disappear when bovine serum albu-
min is included in the incubation medium [23]. Moreover, this
transition is accompanied by increases in the endogenous lev-
els of mitochondrial FFA and in the sensitivity to FFA shown
by both the mitochondrial respiration rate and the membrane
potential, and all of these correlated with the level of UCP3
[61]. These data are in agreement with data published by
Simonyan et al. [25] who, while studying the e¡ect of cold
exposure and T4, reported an increase in UCP3 concentration
and a higher sensitivity of skeletal muscle mitochondria to
added FFA.
As stated above, recent studies in vitro seem to point to-
wards CoQ and superoxide as essential cofactors for the
UCPs-inducible, GDP-sensitive proton-leak, but a physiolog-
ical demonstration of this phenomenon in an in vivo or ex
vivo system is of major importance before we can accept that
it has a physiological meaning.
Some evidence supporting just such a physiological role
came from a recent study [62] in which we showed (a) that
mitochondria from fasting rats, provided they have a source
of FFA, do not show uncoupling despite higher levels of
UCP3, (b) that after T3 administration to these rats, a
GDP-inhibitable, SOD-sensitive uncoupling is observed. In
the same study, we noted that the total amount of CoQ is
drastically reduced in fasting rats, while T3 administration
prevents this reduction. Further, the addition of CoQ to mi-
tochondria from fasting rats (in the presence of an FFA
source) induced UCP3-mediated uncoupling (GDP- and
SOD-sensitive). These results, by providing evidence that in
vivo, as well as in vitro, FFA, CoQ and ROS may be impor-
tant cofactors in the induction of UCP3-mediated uncoupling,
support the idea that T3 is able to stimulate, at one and the
same time, UCP3 expression and activity by virtue of its ca-
pacity to activate integrated biochemical pathways leading to
the establishment of the conditions needed for UCP3 activity:
ROS formation and adequate FFAs and CoQ levels (see Fig.
2).
3. Conclusions and perspectives
The e¡ect of TH on energy metabolism may be explained
by the activation of several biochemical processes integrated
in a complex way. From an analysis of recent results, it seems
clear that UCPs are important mediators of the e¡ects of T3
at the cellular level and that T3 is capable of integrating the
various biochemical pathways involved in UCP expression
and activity, such as those on lipid metabolism, CoQ levels
and ROS production. The objectives of future studies on THs
and UCPs should lie in three basic areas: (1) clari¢cation as
to whether the e¡ects of TH on UCP2/3 are direct or, at least
in part, mediated by other factors such as lipids; (2) improve-
ments in the methods by which mitochondrial functions, re-
lated to the presence of UCPs, can be investigated in vitro; (3)
further clari¢cation of the physiological role played by UCPs,
to which end in vitro studies should be accompanied by in
vivo and ex vivo investigations.
Acknowledgements: The authors wish to thank Dr. D. Ricquier for
reviewing the manuscript and Dr. E. Silvestri for ¢gures and text
editing. This work was supported by Grant COFIN-MIUR 2002.
References
[1] Danforth, E. and Burger, A. (1984) J. Clin. Endocrinol. Metab.
13, 581^595.
[2] Magnus-Levy, A. (1895) Berl. Klin. Wochenschr. 34, 650^654.
[3] Freake, H.C. and Oppenheimer, S.H. (1995) Annu. Rev. Nutr.
15, 263^291.
[4] Lanni, A., Moreno, M., Lombardi, A., de Lange, P. and Goglia,
F. (2001) J. Endocrinol. Invest. 24, 897^913.
[5] Lardy, H.A. and Feldcott, G. (1951) Ann. N.Y. Acad. Sci. 54,
636^648.
[6] Rolfe, D.F.S., Hulbert, A.J. and Brand, M.D. (1994) Biochem.
Biophys. Acta 1118, 405^416.
[7] Brand, M.D., Brindle, K.M., Buckingham, J.A., Harper, J.A.,
Rolfe, D.F. and Stuart, J.A. (1999) Int. J. Obes. Relat. Metab.
Disord. 6, S4^S11.
[8] Jez›ek, P. and Jez›ek, J. (2003) FEBS Lett. 534, 15^25.
[9] Ricquier, D. and Bouillaud, F. (2000) Biochem. J. 345, 161^179.
[10] Liu, X., Rossmeisl, M., McClaine, J. and Kozak, L.P. (2003)
J. Clin. Invest. 111, 399^407.
[11] Pecquer, C., Alves-Guerra, M.C., Gelly, C., Levi-Meyrueis, C.,
Couplan, E., Collins, S., Ricquier, D., Bouillaud, F. and Miroux,
B. (2001) J. Biol. Chem. 276, 8705^8712.
Fig. 2. Schematic representation of the biochemical pathways af-
fected by T3 and related to UCP3 activity. (+) Activation; (?) not
de¢nitively established pathway.
FEBS 27162 7-5-03 Cyaan Magenta Geel Zwart
A. Lanni et al./FEBS Letters 543 (2003) 5^10 9
[12] Boss, O., Hagen, T. and Lowell, B.B. (2000) Diabetes 49, 143^
156.
[13] Jaburek, M., Varecha, M., Gimeno, R.E., Dembski, M., Jezek,
P., Zhang, M., Burn, P., Tartaglia, L.A. and Garlid, K.D. (1999)
J. Biol. Chem. 274, 26003^26007.
[14] Echtay, K.S., Winkler, E., Frischmuth, K. and Klingenberg, M.
(2001) Proc. Natl. Acad. Sci. USA 98, 1416^1421.
[15] Zhang, C.Y., Hagen, T., Mootha, V.K., Slieker, L.J. and Lowell,
B.B. (1999) FEBS Lett. 449, 129^134.
[16] Harper, J.A., Stuart, J.A., Jekabsons, M.B., Roussel, D., Brindle,
K.M., Dickinson, K., Jones, R.B. and Brand, M.D. (2002) Bio-
chem. J. 361, 49^56.
[17] Clapham, J.C., Arch, J.R.S., Chapman, H., Haynes, A., Lister,
C., Moore, G.B.T., Piercy, V., Carter, S.A., Lehner, I., Smith,
S.A., Beeley, L.J., Godden, R.J., Herrity, N., Skehel, M., Chan-
gani, K.K., Hockings, P.D., Reid, D.G., Squires, S.M., Hatcher,
J., Trail, B., Latcham, J., Rastan, S., Harper, A.J., Cadenas, S.,
Buckingham, J.A., Brand, M.D. and Abuin, A. (2000) Nature
406, 415^418.
[18] Gong, D.W., Monemdjou, S., Gavrilova, O., Leon, L.R., Mar-
cus-Samuels, B., Chou, C.J., Everett, C., Kozak, L.P., Li, C.,
Deng, C., Harper, M.E. and Reitman, M. (2000) J. Biol.
Chem. 275, 16251^16257.
[19] Harper, J.A., Stuart, J.A., Jekabsons, M.B., Roussel, D., Brindle,
K.M., Dickinson, K., Jones, R.B. and Brand, M.D. (2002) Bio-
chem. J. 361, 49^56.
[20] Fleury, C., Neverova, M., Collins, S., Raimbault, S., Champigny,
O., Levy-Meyrneis, C., Bouillaud, F., Seldin, M.F., Surwit, R.S.,
Ricquier, D. and Warden, C.H. (1997) Nat. Genet. 15, 269^272.
[21] Gong, D.W., He, Y., Karas, M. and Reitman, M. (1997) J. Biol.
Chem. 272, 24129^24132.
[22] Lanni, A., De Felice, M., Lombardi, A., Moreno, M., Fleury, C.,
Ricquier, D. and Goglia, F. (1997) FEBS Lett. 418, 171^174.
[23] Lanni, A., Beneduce, L., Lombardi, A., Moreno, M., Boss, O.,
Muzzin, P., Giacobino, J.P. and Goglia, F. (1999) FEBS Lett.
444, 250^254.
[24] Cusin, I., Zakrzewska, K.E., Boss, O., Muzzin, P., Giacobino,
J.P., Ricquier, D., Jeanrenaud, B. and Rohner-Jeanrenaud, F.
(1998) Diabetes 47, 1014^1019.
[25] Simonyan, R.A., Jimenez, M., Ceddia, R.B., Giacobino, J.P.,
Muzzin, P. and Skulachev, V.P. (2001) Biochem. Biophys. Acta
1505, 271^279.
[26] Weigle, D.S., Selfridge, L.E., Schwartz, M.W., Seeley, R.J., Cum-
mings, D.E., Havel, P.J., Kuijper, J.L. and BeltrandelRio, H.
(1998) Diabetes 47, 298^302.
[27] Cadenas, S., Buckingham, J.A., Samec, S., Seydoux, J., Din, N.,
Dulloo, A.G. and Brand, M.D. (1999) FEBS Lett. 462, 257^260.
[28] Hesselink, M.K., Greenha¡, P.L., Constantin-Teodosiu, D.,
Hultman, E., Saris, W.H., Nieuwlaat, R., Schaart, G., Kornips,
E. and Schrauwen, P. (2003) J. Clin. Invest. 111, 479^486.
[29] Dulloo, A.G. and Samec, S. (2001) Br. J. Nutr. 86, 1^18.
[30] Medvedev, A.V., Snedden, S.K., Raimbault, S., Ricquier, D. and
Collins, S. (2001) J. Biol. Chem. 276, 10817^10823.
[31] Winkler, E. and Klingenberg, M. (1994) J. Biol. Chem. 269,
2508^2515.
[32] Skulachev, V.P. (1991) FEBS Lett. 294, 158^162.
[33] Nedergaard, J. and Cannon, B. (2003) Exp. Physiol. 88, 65^84.
[34] Nedergaard, J., Golozoubova, V., Matthias, A., Asadi, A., Ja-
cobsson, A. and Cannon, B. (2001) Biochim. Biophys. Acta 1504,
82^106.
[35] Himms-Hagen, J. and Harper, M.E. (2001) Exp. Biol. Med. 226,
78^84.
[36] Skulachev, V.P. (1998) Biochim. Biophys. Acta 1363, 100^124.
[37] Vidal-Puig, A.J., Grujic, D., Zhang, C.Y., Hagen, T., Boss, O.,
Ido, Y., Szcsepanik, A., Wade, J., Mootha, V., Corthright, R.,
Muoio, D.M. and Lowell, B.B. (2000) J. Biol. Chem. 275, 16258^
16266.
[38] Ne'gre-Salvayre, A., Hirtz, C., Carrera, G., Cazenave, R., Troly,
M., Salvayre, R., Pelicaud, L. and Casteilla, L. (1997) FASEB J.
11, 809^815.
[39] Arsenijevic, D., Onurna, H., Pecqueur, C., Raimbault, S., Man-
ning, B.S., Miroux, B., Couplan, E., Alves-Guerra, M.C., Gou-
bern, M., Surwit, R., Bouillaud, F., Richard, D., Collins, S. and
Ricquier, D. (2000) Nat. Genet. 26, 435^439.
[40] Echtay, K.S. and Brand, M.D. (2001) Biochem. Soc. Trans. 29,
763^768.
[41] Couplan, E., del Mar Gonzalez-Barroso, M., Alves-Guerra,
M.C., Ricquier, D., Goubern, M. and Bouillaud, F. (2002)
J. Biol. Chem. 277, 26268^26275.
[42] Echtay, K.M., Roussel, D., St-Pierre, J., Jekabsons, M.B., Cade-
nas, S., Stuart, J.A., Harper, J.A., Roebuck, S.J., Clapham, J.C.
and Brand, M.D. (2002) Nature 415, 96^99.
[43] Yen, P.M. (2001) Physiol. Rev. 81, 1097^1142.
[44] Andersson, U. and Scarpulla, R.C. (2001) Mol. Cell. Biol. 21,
3738^3749.
[45] Jiang, Y., Miltzer, P. and Yen, P.M. (2000) Mol. Endocrinol.
136, 231^239.
[46] Clement, K., Viguerie, N., Diehn, M., Alizadeh, A., Barbe, P.,
Thalamas, C., Storey, J.D., Brown, P.O., Barsh, G.S. and Lan-
gin, D. (2002) Genom. Res. 12, 281^291.
[47] Pillar, T.M. and Seitz, H.J. (1997) Eur. J. Endocrinol. 136, 231^
239.
[48] Scarpulla, R.C. (1996) Trends Cardiovasc. Med. 6, 39^45.
[49] Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M. and
Spiegelman, B.L. (1998) Cell 92, 829^839.
[50] Andersson, U. and Scarpulla, R.C. (2001) Mol. Cell. Biol. 21,
3738^3749.
[51] Gadaleta, M.N., Barletta, A., Caldorazzo, M., De Leo, T. and
Saccone, C. (1972) Eur. J. Biochem. 3, 376^381.
[52] Mutvei, A., Kuzela, S. and Nelson, B.D. (1989) Eur. J. Biochem.
180, 235^240.
[53] Wrutniak-Cabello, C., Casas, F. and Cabello, G. (2001) J. Mol.
Endocrinol. 26, 67^77.
[54] Silva, J.E. and Rabelo, R. (1997) Eur. J. Endocrinol. 136, 251^
264.
[55] Ribeiro, M.O., Carvalho, S.D., Schultz, J.J., Chiellini, G., Scan-
lan, T.S., Bianco, A.C. and Brent, G.A. (2001) J. Clin. Invest.
108, 97^105.
[56] Jucker, B.M., Dufour, S., Ren, J., Cao, X., Previs, S.F., Under-
hill, B., Cadman, K.S. and Shulman, G.I. (2000) Proc. Natl.
Acad. Sci. USA 97, 6880^6884.
[57] Lebon, V., Dufour, S., Petersen, K.F., Ren, J., Jucker, B.M.,
Slezak, L.A., Cline, G.W., Rothman, D.L. and Shulman, G.I.
(2001) J. Clin. Invest. 108, 733^737.
[58] De Lange, P., Lanni, A., Beneduce, L., Moreno, M., Lombardi,
A., Silvestri, E. and Goglia, F. (2001) Endocrinology 142, 3414^
3420.
[59] Barbe, P., Larrouy, D., Boulanger, C., Chevillotte, E., Viguerie,
N., Thamalas, C., Trastoy, M.O., Roques, M., Vidal, H. and
Langin, D. (2001) FASEB J. 15, 13^15.
[60] Moreno, M., Lombardi, A., Beneduce, L., Silvestri, E., Pinna,
G., Goglia, F. and Lanni, A. (2002) Endocrinology 143, 504^510.
[61] Lombardi, A., Silvestri, E., Moreno, M., De Lange, P., Farina,
P., Goglia, F. and Lanni, A. (2002) FEBS Lett. 532, 12^16.
[62] Moreno, M., Lombardi, A., de Lange, P., Silvestri, E., Ragni,
M., Lanni, A. and Goglia, F. (2003) FASEB J., in press.
FEBS 27162 7-5-03 Cyaan Magenta Geel Zwart
A. Lanni et al./FEBS Letters 543 (2003) 5^1010
